Peter J Thomas

US Patent:

7786438, Aug 31, 2010

Filed:

Jul 21, 2008

Appl. No.:

12/176490

Inventors:

Nathan DeVilbiss - Sandia Park NM, US
Ryan Olcott - Rio Rancho NM, US
Peter Thomas - Albuquerque NM, US
Gregory Spanjers - Sandia Park NM, US
James Winter - Albuquerque NM, US
Jason Guarnieri - Albuquerque NM, US
Timothy Klatt - Albuquerque NM, US
Holly Victorson - Albuquerque NM, US
Thomas Roberts - Albuquerque NM, US
Robert Thompson - Marina Del Rey CA, US

Assignee:

The United States of America as represented by the Secretary of the Airforce - Washington DC

International Classification:

G01J 5/00

US Classification:

250332

Abstract:

A sensor assembly that replaces a single focal plane array detector with two focal plane array detectors orientated with respect to each other such that a power splitter divides an incoming light source equally between each detector. The two detectors are selected such that the locations of poorly-operating pixels in each detector do not overlay. The output signals of each detector are then electronically or analytically combined to yield 100 percent operability. Separate switchable wavelength filter wheels having one or more different wavelength filters may be positioned between the power splitter and each of the detectors. The power splitter may be replaced by a polarization splitter. One detector can be translated perpendicular to the incoming light source relative to the second detector to compensate for new poorly-operating pixels and/or to improve the spatial resolution.

US Patent:

48929336, Jan 9, 1990

Filed:

Apr 20, 1988

Appl. No.:

7/183831

Inventors:

Ronald R. Salem - Brookline MA
Peter Thomas - Pembroke MA
Norman Zamcheck - W. Newton MA
Glenn Steele - Swampscott MA

Assignee:

New England Deaconess Hospital Corporation - Boston MA
Mallory Institute of Pathology Foundation - Boston MA

International Classification:

C07K 1500
C12N 500

US Classification:

530387

Abstract:

A monoclonal antibody raised to colorectal carcinoma, and a hybridoma which elicits the antibody, have been produced. This antibody, ND4 has been discovered to react with a new tumor marker, a glycoprotein of approximately 160 kD found on the surface of undifferentiated colorectal carcinoma cells; it does not cross-react with other known tumor markers. It is useful for detecting and monitoring colorectal carcinoma.

US Patent:

49217895, May 1, 1990

Filed:

Apr 20, 1988

Appl. No.:

7/184079

Inventors:

Ronald R. Salem - Brookline MA
Peter Thomas - Pembroke MA
Glenn Steele - Swampscott MA

Assignee:

New England Deaconess Hospital Corporation - Boston MA

International Classification:

G01N 3353
G01N 33566
G01N 33563
C12M 1500

US Classification:

435 7

Abstract:

A new marker for colorectal carcinoma has been discovered which is a glycoprotein having a molecular weight of approximately 160,000 daltons. Assay methods which can identify this marker are useful indetecting, diagnosing, and monitoring colorectal carcinoma, and in particular, carcinoma of the undifferentiated variety which heretofor were not readily detectible. For example, an assay which utilizes an antibody reacting to this glycoprotein marker is useful in a screening method for the detection and monitoring of colorectal carcinoma cells. Such an antibody can be included as part of a kit for screening a patient for colorectal carcinoma.

US Patent:

52410528, Aug 31, 1993

Filed:

Dec 19, 1990

Appl. No.:

7/630551

Inventors:

Carol A. Toth - Sharon MA
Peter Thomas - Pembroke MA

Assignee:

New England Deaconess Hospital Corporation - Boston MA

International Classification:

C07K 300

US Classification:

530395

Abstract:

Disclosed is carcinoma orosomucoid-related antigen (CORA), a glycoprotein which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and is characterized by having a molecular weight of about 46,000-50,000 daltons on SDS-polyacrylamide gels, an isoelectric point of about 3. 0-3. 5, a carbohydrate content of about 25-35% by weight, an amino acid sequence defined in the Sequence Listing by SEQ ID NO:1, reactivity with antisera raised thereto, and substantially no reactivity with antisera raised to nonspecific cross-reacting antigen (NCA) or to CEA. Also disclosed is a method for detecting and monitoring carcinoma.

US Patent:

52450171, Sep 14, 1993

Filed:

May 31, 1991

Appl. No.:

7/708885

Inventors:

Sibusisiwe M. Maswoswe - Ashland MA
Joseph V. Briggman - Westford MA
Carol A. Toth - Sharon MA
Peter Thomas - Pembroke MA

Assignee:

Applied Biotechnology, Inc. - Cambridge MA
New England Deaconess Hospital Corporation - Boston MA

International Classification:

C07K 302
C07K 320
C07K 1506
C07K 1514

US Classification:

530413

Abstract:

Disclosed are methods of isolating a protein which binds carcinoembryonic antigen. These methods include the following steps. A biological sample containing carcinoembryonic antigen (CEA) and a CEA-binding protein (CBP) is provided and contacted with a divalent cation at a concentration and for a time sufficient to allow the binding of the CBP to CEA, thereby forming a CBP-CEA conjugate. The sample is then contacted with an adsorbent that binds CEA for a time sufficient to allow adsorbance to the adsorbent. Portions of the sample not adsorbed are removed. The CBP is then disassociated from the conjugate and is collected.

US Patent:

52044505, Apr 20, 1993

Filed:

Jan 9, 1990

Appl. No.:

7/441368

Inventors:

Carol A. Toth - Westwood MA
Peter Thomas - Pembroke MA

Assignee:

New England Deaconess Hospital Corporation - Boston MA

International Classification:

C07K 1514

US Classification:

530395

Abstract:

Disclosed is a glycoprotein, CORA, which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and can be characterized by having a molecular weight of about 46,000-50,000 daltons, an isoelectric point of about 3. 0-3. 5, a carbohydrate content of about 25-35% by weight, reactivity with antisera raised thereto, and substantially no reactivity with antisera raised to nonspecific cross-reacting antigen (NCA) or to CEA. Also disclosed are a hybridoma which produces a monoclonal antibody to CORA, the monoclonal antibody to CORA, and a device, kit, and method for detecting and monitoring carcinoma.

US Patent:

52816974, Jan 25, 1994

Filed:

May 31, 1991

Appl. No.:

7/708888

Inventors:

Carol A. Toth - Sharon MA
Peter Thomas - Pembroke MA
Sibusisiwe M. Maswoswe - Ashland MA
Joseph V. Briggman - Westford MA

Assignee:

Applied Biotechnology, Inc. - Cambridge MA
New England Deacons Hospital Corp. - Boston MA

International Classification:

A61K 4900
C07K 1506
C07K 1514
G01N 3350

US Classification:

530350

Abstract:

Disclosed is a protein that specifically binds carcinoembryonic actigen (CEA) in the presence of divalent cation in vitro. This protein has a molecular weight of about 20 kD as determined by SDS-polyacrylamide gel electrophoresis, is glycosylated, and includes the amino acid sequence set forth in the Sequence Listing as SEQ ID NO:4. Also disclosed are antibodies that recognize the CEA binding protein, methods of detecting carcinoma, methods of treating carcinoma, and a kit for screening a patient for carcinoma.

US Patent:

52782905, Jan 11, 1994

Filed:

May 31, 1991

Appl. No.:

7/714386

Inventors:

Peter Thomas - Pembroke MA
Carol A. Toth - Sharon MA
Sibusisiwe M. Maswoswe - Ashland MA
Joseph V. Briggman - Westford MA

Assignee:

Applied Biotechnology, Inc. - Cambridge MA
New England Deaconess Hospital, Corp. - Boston MA

International Classification:

A61K 4900
C07K 1506
C07K 1514
G01N 3350

US Classification:

530395

Abstract:

Disclosed is a protein that specifically binds carcinoembryonic actigen (CEA) in the presence of divalent cation in vitro. This protein has a molecular weight of about 21 kD as determined by SDS-polyacrylamide gel electrophoresis, is glycosylated, and includes the amino acid sequence set forth in the Sequence Listing as SEQ ID NO: 2. Also disclosed are antibodies that recognize the CEA binding protein, methods of detecting carcinoma, methods of treating carcinoma, and a kit for screening a patient for carcinoma.